MYL12A and triple-A syndrome: In line with the D-AAA-SMCs, metformin significantly decreased the gene expression of MYL12A (p = 0.015), a cytoskeletal marker that showed higher protein expression in ND-AAA-SMCs compared to C-SMCs and D-AAA-SMCs in the proteomics analysis (Figure S5A).